• Publications
  • Influence
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
BACKGROUND Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS In thisExpand
  • 5,395
  • 270
  • PDF
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
BACKGROUND Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for progressive disease. We assessed the efficacy ofExpand
  • 3,375
  • 171
  • PDF
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised
BACKGROUND Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) withExpand
  • 3,964
  • 147
  • PDF
Pembrolizumab for the treatment of non-small-cell lung cancer.
BACKGROUND We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. WeExpand
  • 2,955
  • 120
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown. Expand
  • 2,005
  • 105
  • PDF
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.
BACKGROUND The EGFR T790M mutation is the most common mechanism of drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients who have lung cancer with an EGFRExpand
  • 1,376
  • 94
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
BACKGROUND First‐line therapy for advanced non–small‐cell lung cancer (NSCLC) that lacks targetable mutations is platinum‐based chemotherapy. Among patients with a tumor proportion score forExpand
  • 1,930
  • 82
  • PDF
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
S. Peters1, A.A. Adjei2, C. Gridelli3, M. Reck4, K. Kerr5 & E. Felip6 on behalf of the ESMO Guidelines Working Group* Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland;Expand
  • 617
  • 35
Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M
Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinaseExpand
  • 653
  • 34
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
The Clatterbridge Cancer Centre and Liverpool Heart and Chest Hospital, Liverpool; University of Aberdeen, Aberdeen, UK; Center for Medical Imaging, University of Groningen, Groningen; Department ofExpand
  • 716
  • 26
  • PDF